Comparative Pharmacology
Head-to-head clinical analysis: OLAPARIB versus TALZENNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OLAPARIB versus TALZENNA.
OLAPARIB vs TALZENNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Poly (ADP-ribose) polymerase (PARP) inhibitor that blocks base excision repair, leading to accumulation of DNA double-strand breaks and cell death in tumors with homologous recombination repair deficiency.
Talazoparib is a poly (ADP-ribose) polymerase (PARP) inhibitor, including PARP1 and PARP2, which plays a role in DNA repair. It traps PARP on single-strand breaks, leading to replication fork collapse, double-strand breaks, and cell death in tumors with homologous recombination repair deficiencies, such as BRCA mutations.
300 mg orally twice daily, taken with or without food. For patients with BRCA-mutated advanced ovarian cancer after ≥3 prior lines of chemotherapy; or as maintenance therapy after platinum-based chemotherapy for recurrent ovarian cancer; or for HER2-negative metastatic breast cancer with germline BRCA mutation; or for metastatic pancreatic adenocarcinoma with germline BRCA mutation after first-line platinum-based chemotherapy; or for metastatic castration-resistant prostate cancer with HRR gene mutations.
800 mg orally once daily with or without food.
None Documented
None Documented
Clinical Note
moderateOlaparib + Digoxin
"Olaparib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateOlaparib + Digitoxin
"Olaparib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateOlaparib + Deslanoside
"Olaparib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateOlaparib + Acetyldigitoxin
"Olaparib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life ~11-12 hours; steady-state reached by day 3-5; supports BID dosing
Terminal elimination half-life is approximately 90 hours (range 74-109 hours). The long half-life supports once-daily dosing and allows for sustained poly(ADP-ribose) polymerase (PARP) inhibition.
Fecal (84%), renal (6%) as unchanged drug; <1% in urine as metabolites
Talazoparib is eliminated primarily via biliary/fecal excretion (68.7%) and renal excretion (19.1%). Approximately 11% is excreted unchanged in feces and <1% unchanged in urine.
Category C
Category C
PARP Inhibitor
PARP Inhibitor